Business Model Breakdown
How Harmony Biosciences Holdings Inc Makes Money
HRMY
Market Cap
$1.8B
Annual Revenue
$868M
Profit Margin
18.3%
Employees
268
The Short Version
Harmony Biosciences is a commercial-stage biopharmaceutical company that focuses on developing and commercializing innovative therapies for patients with rare neurological disorders who have unmet medical needs. Its primary and currently sole marketed product is WAKIX (pitolisant), approved for the treatment of excessive daytime sleepiness (EDS) or cataplexy in adult patients with narcolepsy, and more recently for EDS in adult patients with idiopathic hypersomnia. The company makes money by manufacturing, marketing, and selling WAKIX to patients via specialized pharmacies and directly to healthcare providers.
Where the Revenue Comes From
WAKIX (pitolisant) net product sales (~100% of current revenue)
Who buys: Patients diagnosed with narcolepsy or idiopathic hypersomnia, prescribed by neurologists and sleep specialists.
Why It Works (Competitive Advantages)
- ✔Niche focus and established commercial footprint for rare neurological disorders.
- ✔Patent protection and regulatory exclusivity for WAKIX.
- ✔Strong average revenue growth rate (27.3% annually) outperforming the broader pharmaceutical sector.
Economic Moat: Narrow (Intangible Assets/IP (Patents for pitolisant (WAKIX) and related formulations), Switching Costs (Established patient base on effective treatment, physician familiarity))
What Our Analysis Says
DVR Score as of April 26, 2026
Harmony Biosciences maintains a strong core business anchored by WAKIX, with 2026 revenue guidance reiterated at $1.0-$1.04 billion, indicating continued market penetration and robust growth (21.1% YoY revenue growth in Q4 2025). The company's attractive valuation (P/E 11.84, PEG 0.43) and strong average annual earnings growth (32.6%) suggest undervaluation relative to its sector. However, the significant Q4 2025 EPS miss and 55.3% YoY decline raise concerns about short-term profitability quality, impacting overall confidence. New executive appointments are positive for leadership but don't immediately derisk the high bar for 10x growth, which remains highly dependent on successful pipeline diversification or transformative M&A. The risk/reward for the core business is attractive, but true 'moonshot' potential for 10x is not yet fully in sight without further catalysts.